Научно-исследовательский центр «Онкотераностика»

Публикации и достижения центра

  1. Aleksei E. Machulkin, Stanislav A. Petrov, Vitalina Bodenko, Mariia S. Larkina, Evgenii Plotnikov, Feruza Yuldasheva, Maria Tretyakova, Ekaterina Bezverkhniaia, Nikolay Yu. Zyk, Elena Stasyuk, Roman Zelchan, Alexander G. Majouga, Vladimir Tolmachev, Anna Orlova, Elena K. Beloglazkina, and Mekhman S. Yusubov, Synthesis and Preclinical Evaluation of Urea-Based Prostate-Specific Membrane Antigen-Targeted Conjugates Labeled with 177Lu, ACS Pharmacology & Translational Science 2024 7 (5), 1457-1473, DOI: 10.1021/acsptsci.4c00070
  2. Bodenko V.V., Larkina M.S., Prach A.A., Plotnikov E.V., Belousov M.V., Chernov V.I. Molecular targets for metastasis-directed therapy in malignant tumors. Bulletin of Siberian Medicine. 2024;23(2):101-113. https://doi.org/10.20538/1682-0363-2024-2-101-113
  3. Zelchan, R.; Chernov, V.; Medvedeva, A.; Rybina, A.; Bragina, O.; Mishina, E.; Larkina, M.; Varvashenya, R.; Fominykh, A.; Schulga, A.; et al. Phase I Clinical Evaluation of Designed Ankyrin Repeat Protein [99mTc]Tc(CO)3-(HE)3-Ec1 for Visualization of EpCAM-Expressing Lung Cancer. Cancers 2024, 16, 2815. https://doi.org/10.3390/cancers16162815
  4. Deyev SM, Oroujeni M, Garousi J, Gräslund T, Li R, Rosly AHB, Orlova A, Konovalova E, Schulga A, Vorobyeva A, et al. Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion. International Journal of Molecular Sciences. 2024; 25(8):4246. https://doi.org/10.3390/ijms25084246
  5. Maria Larkina, Ruslan Varvashenya, Feruza Yuldasheva, Evgenii Plotnikov, Ekaterina Bezverkhniaia, Maria Tretyakova, Roman Zelchan, Alexey Schulga, Elena Konovalova, Anzhelika Vorobyeva, Mikhail Belousov, Anna Orlova, Vladimir Tolmachev, and Sergey Deyev, Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins G3 for the 99mTc-Based Imaging of HER2-Expressing Malignant Tumors, Molecular Pharmaceutics 2024 21 (4), 1919-1932 DOI: 10.1021/acs.molpharmaceut.3c01173
  6. Plotnikov E.V., Belousov M.V., Brazovsky K.S., Larkina M.S., Artamonov A.A., Stuchebrov S.G., Chernov V.I. Experimental study of radioprotective properties of lithium pyruvate in vitro. Siberian journal of oncology. 2024;23(4):66-76. (In Russ.) https://doi.org/10.21294/1814-4861-2024-23-4-66-76
  7. Jie Zhang, Vitalina Bodenko, Maria Larkina, Ekaterina Bezverkhniaia, Tianqi Xu, Yunqi Liao, Ayman Abouzayed, Evgenii Plotnikov, Maria Tretyakova, Feruza Yuldasheva, Mikhail V. Belousov, Anna Orlova, Vladimir Tolmachev, Torbjörn Gräslund, Anzhelika Vorobyeva, Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation., Journal of Controlled Release,Volume 370,2024,Pages 468-478, https://doi.org/10.1016/j.jconrel.2024.04.051
  8. Варвашеня Р.Н., Прач А.А., Плотников Е.B., Деев С.М., Белоусов М.В., Ларькина М.С., Чернов В.И. Оценка функциональной пригодности лиофилизата таргетных каркасных белков с анкириновыми повторами для радионуклидной визуализации гиперэкспрессии HER2/neu в злокачественных опухолях. Бюллетень сибирской медицины. 2024;23(3):16-24. https://doi.org/10.20538/1682-0363-2024-3-16-24
  9. Хасново Л.А. Новые Способы Синтеза Двух Простетических Групп ([123I]SIB и [123I]IHPEM) для Радиоиодирования Каркасных Белков. / Хасново Л.А., Ларькина М.С., Янович Г.Е., Варвашеня Р.Н., Плотников Е.В., Шульга А.А., Коновалова Е.В., Большаков А.М., Гарапацкий А.А., Деев С.М., Юсубов М.С. // Бутлеровские сообщения. 2024. Т.79. №7. C.67-80. DOI: 10.37952/ROI-jbc-01/24-79-7-67.
  1. Abouzayed, A.; Seitova, K.; Lundmark, F.; Bodenko, V.; Oroujeni, M.; Tolmachev, V.; Rosenström, U.; Orlova, A. 177Lu-Labeled PSMA Targeting Therapeutic with Optimized Linker for Treatment of Disseminated Prostate Cancer; Evaluation of Biodistribution and Dosimetry. Front Oncol 2023, 13, 1221103. https://doi.org/10.3389/fonc.2023.1221103
  2. Abouzayed, A.; Borin, J.; Lundmark, F.; Rybina, A.; Hober, S.; Zelchan, R.; Tolmachev, V.; Chernov, V.; Orlova, A. The GRPR Antagonist [99mTc]Tc-maSSS-PEG2-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity. Diagnostics (Basel) 2023, 13 (9), 1611. https://doi.org/10.3390/diagnostics13091611
  3. Bragina, O.; Chernov, V.; Schulga, A.; Konovalova, E.; Hober, S.; Deyev, S.; Sörensen, J.; Tolmachev, V. Direct Intra-Patient Comparison of Scaffold Protein-Based Tracers, [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3, for Imaging of HER2-Positive Breast Cancer. Cancers (Basel) 2023, 15 (12), 3149. https://doi.org/10.3390/cancers15123149
  4. Bragina, O.; Chernov, V.; Larkina, M.; Rybina, A.; Zelchan, R.; Garbukov, E.; Oroujeni, M.; Loftenius, A.; Orlova, A.; Sörensen, J.; Frejd, F. Y.; Tolmachev, V. Phase I Clinical Evaluation of 99mTc-Labeled Affibody Molecule for Imaging HER2 Expression in Breast Cancer. Theranostics 2023, 13 (14), 4858–4871. https://doi.org/10.7150/thno.86770
  5. Bezverkhniaia, E.; Kanellopoulos, P.; Abouzayed, A.; Larkina, M.; Oroujeni, M.; Vorobyeva, A.; Rosenström, U.; Tolmachev, V.; Orlova, A. Preclinical Evaluation of a Novel High-Affinity Radioligand [99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA). Int J Mol Sci 2023, 24 (24), 17391 https://doi.org/10.3390/ijms242417391
  6. Bogdanchikova, N.; Maklakova, M.; Villarreal-Gómez, L. J.; Nefedova, E.; Shkil, N. N.; Plotnikov, E.; Pestryakov, A. Revealing the Second and the Third Causes of AgNPs Property to Restore the Bacterial Susceptibility to Antibiotics. Int J Mol Sci 2023, 24 (9). https://doi.org/10.3390/IJMS24097854
  7. Badaraev, A. D.; Tran, T. H.; Drozd, A. G.; Plotnikov, E. V.; Dubinenko, G. E.; Kozelskaya, A. I.; Rutkowski, S.; Tverdokhlebov, S. I. Effect of PLGA Concentration in Electrospinning Solution on Biocompatibility, Morphology and Mechanical Properties of Nonwoven Scaffolds. Technologies (Basel) 2023, 11 (5). https://doi.org/10.3390/TECHNOLOGIES11050137
  8. Chernov, V.; Rybina, A.; Zelchan, R.; Medvedeva, A.; Bragina, O.; Lushnikova, N.; Doroshenko, A.; Usynin, E.; Tashireva, L.; Vtorushin, S.; Abouzayed, A.; Rinne, S. S.; Sörensen, J.; Tolmachev, V.; Orlova, A. Phase I Trial of [99mTc]Tc-maSSS-PEG2-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors. Cancers (Basel) 2023, 15 (6), 1631. https://doi.org/10.3390/cancers15061631
  9. Hasnowo, L. A.; Larkina, M. S.; Plotnikov, E.; Bodenko, V.; Yuldasheva, F.; Stasyuk, E.; Petrov, S. A.; Zyk, N. Y.; Machulkin, A. E.; Vorozhtsov, N. I.; Beloglazkina, E. K.; Nenajdenko, V. G.; Tolmachev, V.; Orlova, A.; Majouga, A. G.; Yusubov, M. S. Synthesis, 123I-Radiolabeling Optimization, and Initial Preclinical Evaluation of Novel Urea-Based PSMA Inhibitors with a Tributylstannyl Prosthetic Group in Their Structures. IJMS 2023, 24 (15), 12206. https://doi.org/10.3390/ijms241512206
  10. Hasnowo, L. A.; Larkina, M. S.; Garapatski, A. A.; Yusubov, M. S. The Development of Cyclotron-Based Radiopharmaceuticals: A Comprehensive Review of 64Cu and 123I-Radiolabeled Urea-Based Small Molecule PSMA Ligands. J Radioanal Nucl Chem 2023, 332 (9), 3523–3546. https://doi.org/10.1007/s10967-023-09048-3
  11. Ilyin, V.; Orlov, O.; Skedina, M.; Korosteleva, A.; Molodtsova, D.; Plotnikov, E.; Artamonov, A. Mathematical Model of Antibiotic Resistance Determinants’ Stability Under Space Flight Conditions. Astrobiology 2023, 23 (4), 407–414. https://doi.org/10.1089/AST.2022.0076
  12. Fatkullin, M.; Rodriguez, R. D.; Petrov, I.; Villa, N. E.; Lipovka, A.; Gridina, M.; Murastov, G.; Chernova, A.; Plotnikov, E.; Averkiev, A.; Cheshev, D.; Semyonov, O.; Gubarev, F.; Brazovskiy, K.; Sheng, W.; Amin, I.; Liu, J.; Jia, X.; Sheremet, E. Molecular Plasmonic Silver Forests for the Photocatalytic-Driven Sensing Platforms. Nanomaterials 2023, 13 (5). https://doi.org/10.3390/NANO13050923
  13.  Larkina, M.; Plotnikov, E.; Bezverkhniaia, E.; Shabanova, Y.; Tretyakova, M.; Yuldasheva, F.; Zelchan, R.; Schulga, A.; Konovalova, E.; Vorobyeva, A.; Garousi, J.; Gräslund, T.; Belousov, M.; Tolmachev, V.; Deyev, S. Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with 99mTc for Radionuclide Imaging of HER2 Expression in Cancer. Int J Mol Sci 2022, 23 (21). https://doi.org/10.3390/IJMS232113443
  14. Liu, Y.; Xu, T.; Vorobyeva, A.; Loftenius, A.; Bodenko, V.; Orlova, A.; Frejd, F. Y.; Tolmachev, V. Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab. Cancers (Basel) 2023, 15 (9), 2409. https://doi.org/10.3390/cancers15092409
  15. Mensah, G. A.; Fuster, V.; Murray, C. J. L.; Roth, G. A. Global Burden of Cardiovascular Diseases and Risks, 1990-2022. J Am Coll Cardiol 2023, 82 (25), 2350–2473. https://doi.org/10.1016/J.JACC.2023.11.007
  16. Oroujeni, M.; Bezverkhniaia, E. A.; Xu, T.; Liu, Y.; Plotnikov, E. V.; Klint, S.; Ryer, E.; Karlberg, I.; Orlova, A.; Frejd, F. Y.; Tolmachev, V. Evaluation of Affinity Matured Affibody Molecules for Imaging of the Immune Checkpoint Protein B7-H3. Nucl Med Biol 2023, 124–125, 108384. https://doi.org/10.1016/j.nucmedbio.2023.108384
  17. Plotnikov, E. V.; Tretayakova, M. S.; Garibo-Ruíz, D.; Rodríguez-Hernández, A. G.; Pestryakov, A. N.; Toledano-Magaña, Y.; Bogdanchikova, N. A Comparative Study of Cancer Cells Susceptibility to Silver Nanoparticles Produced by Electron Beam. Pharmaceutics 2023, 15 (3). https://doi.org/10.3390/PHARMACEUTICS15030962
  18. Plotnikov, E.; Pukhnyarskaya, D.; Chernova, A. Lithium and Microorganisms: Biological Effects and Mechanisms. Curr Pharm Biotechnol 2023, 24 (13), 1623–1629. https://doi.org/10.2174/1389201024666230302153849
  19. Tolmachev, V.; Bodenko, V.; Orlova, A.; Schulga, A.; Deyev, S. M.; Vorobyeva, A. Visualization of Epithelial Cell Adhesion Molecule-Expressing Renal Cell Carcinoma Xenografts Using Designed Ankyrin Repeat Protein Ec1 Labelled with 99mTc and 125I. Oncol Lett 2023, 25 (1), 12. https://doi.org/10.3892/ol.2022.13598
  20. Tolmachev, V.; Bragina, O.; Chernov, V.; Larkina, M.; Rybina, A.; Zelchan, R.; Oroujeni, M.; Loftenius, A.; Orlova, A.; Sorensen, J.; Frejd, F. HER2-Specific Affibody Molecule [99mTc]Tc-ZHER2:41071: Phase I Clinical Trial. Nucl Med Biol 2023, 126–127, 108652. https://doi.org/10.1016/J.NUCMEDBIO.2023.108652
  21. Tretyakova, M. S.; Krivoshchekov, S. V.; Plotnikov, E. V.; Dorozhko, E. V.; Voronova, O. A.; Larkina, M. S.; Brazovskiy, K. S.; Belousov, M. V. Standardization of the Pharmaceutical Substance of Lithium Salt Gamma-Lactone of 2,3-Dehydro-l-Gulonic Acid as a Radio-Sensitizing Agent. Razrabotka i registraciâ lekarstvennyh sredstv 2023, 12 (3), 125–133. https://doi.org/10.33380/2305-2066-2023-12-3-125-133
  22. Tretyakova, M. S.; Drozd, A. G.; Belousov, M. V.; Brazovskiy, K. S.; Larkina, M. S.; Krivoshchekov, S. V.; Artamonov, A. A.; Miloichikova, I. A.; Bezmaga, A. V.; Bolshakov, A. M.; Sukhikh, E. S.; Plotnikov, E. V. Study of the Radiosensitizing Action of Lithium Ascorbate Under Neutron and Photon Irradiation of Tumor Cells. Razrabotka i registraciâ lekarstvennyh sredstv 2023, 12 (2), 185–189. https://doi.org/10.33380/2305-2066-2023-12-2-185-189
  23. Tretayakova, M.; Brazovskii, K.; Belousov, M.; Artamonov, A.; Stuchebrov, S.; Gogolev, A.; Larkina, M.; Sukhikh, E.; Plotnikov, E. Radiosensitizing Effects of Lithium Ascorbate on Normal and TumorLymphoid Cells under X-Ray Irradiation. CBC 2023, 19 (8), e030523216456. https://doi.org/10.2174/1573407219666230503094421
  24. Tretyakova, M. S.; Krivoshchekov, S. V.; Plotnikov, E. V.; Dorozhko, E. V.; Voronova, O. A.; Larkina, M. S.; Brazovskiy, K. S.; Belousov, M. V. Standardization of the Pharmaceutical Substance of Lithium Salt Gamma-Lactone of 2,3-Dehydro-l-Gulonic Acid as a Radio-Sensitizing Agent. Drug Development and Registration 2023, 12 (3), 125–133. https://doi.org/10.33380/2305-2066-2023-12-3-125-133
  25. Votkina, D. E.; Abramov, A. A.; Kovalskaya, E. S.; Plotnikov, E. V.; Postnikov, P. S.; Stepanova, E. V.; Petunin, P. V. Sweetened Alkylated Verdazyls Effectively Kill Cancer Cells under Light Irradiation. ChemMedChem 2023, 18 (11). https://doi.org/10.1002/CMDC.202300026
  26. Xu, T.; Schulga, A.; Konovalova, E.; Rinne, S. S.; Zhang, H.; Vorontsova, O.; Orlova, A.; Deyev, S. M.; Tolmachev, V.; Vorobyeva, A. Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model. Int J Mol Sci 2023, 24 (3), 2838. https://doi.org/10.3390/ijms24032838
  27. Yin, W.; Xu, T.; Ding, H.; Zhang, J.; Bodenko, V.; Tretyakova, M. S.; Belousov, M. V.; Liu, Y.; Oroujeni, M.; Orlova, A.; Tolmachev, V.; Gräslund, T.; Vorobyeva, A. Comparison of HER2-Targeted Affibody Conjugates Loaded with Auristatin- and Maytansine-Derived Drugs. J Control Release 2023, 355, 515–527. https://doi.org/10.1016/j.jconrel.2023.02.005

  1. Bragina, O. D.; Deyev, S. M.; Chernov, V. I.; Tolmachev, V. M. The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer. Acta Naturae 2022, 14 (2), 4–15. https://doi.org/10.32607/actanaturae.11611.
  2. Bragina, O.; Chernov, V.; Schulga, A.; Konovalova, E.; Garbukov, E.; Vorobyeva, A.; Orlova, A.; Tashireva, L.; Sörensen, J.; Zelchan, R.; Medvedeva, A.; Deyev, S.; Tolmachev, V. Phase I Trial of 99mTc-(HE)3-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer. J Nucl Med 2022, 63 (4), 528–535. https://doi.org/10.2967/jnumed.121.262542.
  3. Botkina, O.; Plotnikov, E. Cytotoxic Effects of Homeopathic Preparations on Human Tumor Cells In Vitro. Curr Bioact Compd 2022, 19 (3). https://doi.org/10.2174/1573407218666220509184504.
  4. Sviridova, E.; Barras, A.; Addad, A.; Plotnikov, E.; Di Martino, A.; Deresmes, D.; Nikiforova, K.; Trusova, M.; Szunerits, S.; Guselnikova, O.; Postnikov, P.; Boukherroub, R. Surface Modification of Carbon Dots with Tetraalkylammonium Moieties for Fine Tuning Their Antibacterial Activity. Biomaterials Advances 2022, 134. https://doi.org/10.1016/J.MSEC.2022.112697.
  5. Schepetkin, I. A.; Chernysheva, G. A.; Aliev, O. I.; Kirpotina, L. N.; Smol’yakova, V. I.; Osipenko, A. N.; Plotnikov, M. B.; Kovrizhina, A. R.; Khlebnikov, A. I.; Plotnikov, E. V.; Quinn, M. T. Neuroprotective Effects of the Lithium Salt of a Novel JNK Inhibitor in an Animal Model of Cerebral Ischemia–Reperfusion. Biomedicines 2022, 10 (9). https://doi.org/10.3390/BIOMEDICINES10092119.
  6. Ilyin, V. K.; Orlov, O. I.; Morozova, Y. A.; Skedina, M. A.; Vladimirov, S. K.; Plotnikov, E. V.; Artamonov, A. A. Prognostic Model for Bacterial Drug Resistance Genes Horizontal Spread in Space-Crews. Acta Astronaut 2022, 190, 388–394. https://doi.org/10.1016/J.ACTAASTRO.2021.10.016.
  7. Tolmachev, V.; Vorobyeva, A. Radionuclides in Diagnostics and Therapy of Malignant Tumors: New Development. Cancers (Basel) 2022, 14 (2), 297. https://doi.org/10.3390/cancers14020297.
  8. Tolmachev, V.; Bodenko, V.; Oroujeni, M.; Deyev, S.; Konovalova, E.; Schulga, A.; Lindbo, S.; Hober, S.; Bragina, O.; Orlova, A.; Vorobyeva, A. Direct In Vivo Comparison of 99mTc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy. Int J Mol Sci 2022, 23 (23), 15181. https://doi.org/10.3390/ijms232315181.
  9. lmachev, V.; Karlström, A. E. Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing Xenografts. J Nucl Med 2022, 63 (7), 1046–1051. https://doi.org/10.2967/jnumed.121.262123.
  10. Oroujeni, M.; Bezverkhniaia, E. A.; Xu, T.; Liu, Y.; Plotnikov, E. V.; Karlberg, I.; Ryer, E.; Orlova, A.; Tolmachev, V.; Frejd, F. Y. Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3. Pharmaceutics 2022, 14 (9), 1780. https://doi.org/10.3390/pharmaceutics14091780.
  11. Liu, Y.; Yu, S.; Xu, T.; Bodenko, V.; Orlova, A.; Oroujeni, M.; Rinne, S. S.; Tolmachev, V.; Vorobyeva, A.; Gräslund, T. Preclinical Evaluation of a New Format of 68Ga- and 111In-Labeled Affibody Molecule ZIGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT. Pharmaceutics 2022, 14 (7), 1475. https://doi.org/10.3390/pharmaceutics14071475.
  12. Liu, Y.; Vorobyeva, A.; Orlova, A.; Konijnenberg, M. W.; Xu, T.; Bragina, O.; Loftenius, A.; Rosander, E.; Frejd, F. Y.; Tolmachev, V. Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule 188Re-ZHER2:41071. Pharmaceutics 2022, 14 (5), 1092. https://doi.org/10.3390/pharmaceutics14051092.
  13. Nikiforova, K.; Gorbunova, A.; Plotnikov, E.; Postnikov, P.; Guselnikova, O. Antifouling Surface for Biomedical Devices: Modification of COC Surface by Quaternary Ammonium Moieties via Diazonium Chemistry. Appl Surf Sci 2022, 603. https://doi.org/10.1016/J.APSUSC.2022.154415.
  14. `Xu, T.; Zhang, J.; Oroujeni, M.; Tretyakova, M. S.; Bodenko, V.; Belousov, M. V.; Orlova, A.; Tolmachev, V.; Vorobyeva, A.; Gräslund, T. Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2. Pharmaceutics 2022, 14 (3), 522. https://doi.org/10.3390/pharmaceutics14030522.
  15. Liu, Y.; Güler, R.; Liao, Y.; Vorobyeva, A.; Widmark, O.; Meuleman, T. J.; Koijen, A.; van den Bos, L. J.; Naasz, R.; Bodenko, V.; Orlova, A.; Ekblad, C.; Tolmachev, V.; Frejd, F. Y. Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis. Pharmaceutics 2022, 14 (11), 2519. https://doi.org/10.3390/pharmaceutics14112519.
  16. Liu, Y.; Yu, S.; Xu, T.; Bodenko, V.; Orlova, A.; Oroujeni, M.; Rinne, S. S.; Tolmachev, V.; Vorobyeva, A.; Gräslund, T. Preclinical Evaluation of a New Format of 68Ga- and 111In-Labeled Affibody Molecule ZIGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT. Pharmaceutics 2022, 14 (7), 1475. https://doi.org/10.3390/pharmaceutics14071475.
  17. Liu, Y.; Güler, R.; Liao, Y.; Vorobyeva, A.; Widmark, O.; Meuleman, T. J.; Koijen, A.; van den Bos, L. J.; Naasz, R.; Bodenko, V.; Orlova, A.; Ekblad, C.; Tolmachev, V.; Frejd, F. Y. Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis. Pharmaceutics 2022, 14 (11), 2519. https://doi.org/10.3390/pharmaceutics14112519. 
  18. Larkina, M.; Plotnikov, E.; Bezverkhniaia, E.; Shabanova, Y.; Tretyakova, M.; Yuldasheva, F.; Zelchan, R.; Schulga, A.; Konovalova, E.; Vorobyeva, A.; Garousi, J.; Gräslund, T.; Belousov, M.; Tolmachev, V.; Deyev, S. Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with 99mTc for Radionuclide Imaging of HER2 Expression in Cancer. Int J Mol Sci 2022, 23 (21), 13443. https://doi.org/10.3390/ijms232113443.
  19. Larkina, M.; Plotnikov, E.; Bezverkhniaia, E.; Shabanova, Y.; Tretyakova, M.; Yuldasheva, F.; Zelchan, R.; Schulga, A.; Konovalova, E.; Vorobyeva, A.; Garousi, J.; Gräslund, T.; Belousov, M.; Tolmachev, V.; Deyev, S. Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with 99mTc for Radionuclide Imaging of HER2 Expression in Cancer. Int J Mol Sci 2022, 23 (21). https://doi.org/10.3390/IJMS232113443.
  20. Garousi, J.; Xu, T.; Liu, Y.; Vorontsova, O.; Hober, S.; Orlova, A.; Tolmachev, V.; Gräslund, T.; Vorobyeva, A. Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart. Pharmaceutics 2022, 14 (8), 1612. https://doi.org/10.3390/pharmaceutics14081612.
  21. Guselnikova, O.; Nugraha, A. S.; Na, J.; Postnikov, P.; Kim, H. J.; Plotnikov, E.; Yamauchi, Y. Surface Filtration in Mesoporous Au Films Decorated by Ag Nanoparticles for Solving SERS Sensing Small Molecules in Living Cells. ACS Appl Mater Interfaces 2022, 14 (36), 41629–41639. https://doi.org/10.1021/ACSAMI.2C12804
  22. Chernov, V.; Dudnikova, E.; Zelchan, R.; Medvedeva, A.; Rybina, A.; Bragina, O.; Goldberg, V.; Muravleva, A.; Sörensen, J.; Tolmachev, V. Phase I Clinical Trial Using [99mTc]Tc-1-Thio-D-Glucose for Diagnosis of Lymphoma Patients. Pharmaceutics 2022, 14 (6), 1274. https://doi.org/10.3390/pharmaceutics14061274.
  23. Chernova, A.; Pukhniarskaia, D.; Biryukov, M.; Plotnikov, E. Influence of Lithium Salt on Escherichia Coli Growth and Viability. Industrial Biotechnology 2022, 18 (1), 32–37. https://doi.org/10.1089/IND.2021.0006.
  24. Plotnikov, E.; Plotnikov, V. Investigation of Antiblastic and Antibacterial Properties of Binuclear Platinum (II)-Interferon Conjugate. Curr Bioact Compd 2022, 18 (7). https://doi.org/10.2174/1573407218666220112112008.
  25. Plotnikov, E.; Plotnikov, V. Antibacterial and Phagocytic Properties of a Novel Silver-Interferon Complex. Antiinfect Agents 2022, 20 (4). https://doi.org/10.2174/2211352520666220404143923.
  26. Votkina, D. E.; Plotnikov, E. V.; Petunin, P. V.; Berdinskaya, E. S.; Tretyakova, M. S.; Audran, G.; Marque, S. R. A.; Postnikov, P. S. Alkylverdazyls as a Source of Alkyl Radicals for Light-Triggered Cancer Cell Death. Mol Pharm 2022, 19 (1), 354–357. https://doi.org/10.1021/ACS.MOLPHARMACEUT.1C00780.
  27. Voronova, O.; Zhuravkov, S.; Korotkova, E.; Artamonov, A.; Plotnikov, E. Antioxidant Properties of New Phenothiazine Derivatives. Antioxidants 2022, 11 (7). https://doi.org/10.3390/ANTIOX11071371.
  1. Bragina, O., von Witting, E., Garousi, J., Zelchan, R., Sandström, M., Orlova, A., Medvedeva, A., Doroshenko, A., Vorobyeva, A., Lindbo, S., Borin, J., Tarabanovskaya, N., Sörensen, J., Hober, S., Chernov, V., & Tolmachev, V. Phase I Study of 99mTc-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer //Journal of nuclear medicine. – 2021. – Vol. 62. – No. 4. – P. 493–499.
    DOI:10.2967/jnumed.120.248799
    https://jnm.snmjournals.org/content/62/4/493
  2. Bragina, O., Chernov, V., Schulga, A., Konovalova, E., Garbukov, E., Vorobyeva, A., Orlova, A., Tashireva, L., Sorensen, J., Zelchan, R., Medvedeva, A., Deyev, S., & Tolmachev, V. Phase I trial of 99mTc-(HE)3-G3, a DARPin-based probe for imaging of HER2 expression in breast cancer //Journal of nuclear medicine: official publication, Society of Nuclear Medicine.– 2021. – jnumed.121.262542. Advance online publication. 
    DOI:10.2967/jnumed.121.262542
    https://jnm.snmjournals.org/content/early/2021/08/12/jnumed.121.262542
  3. Tano, H., Oroujeni, M., Vorobyeva, A., Westerlund, K., Liu, Y., Xu, T., Vasconcelos, D., Orlova, A., Karlström, A.E., Tolmachev, V. Comparative Evaluation of Novel 177Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting //Cancers. – 2021. – Vol. 13. – No. 3. – P. 500. 
    DOI: 10.3390/cancers13030500  
    https://www.mdpi.com/2072-6694/13/3/500
  4. Garousi, J., von Witting, E., Borin, J., Vorobyeva, A., Altai, M., Vorontsova, O., Konijnenberg, M.W., Oroujeni, M., Orlova, A., Tolmachev, V.  Hober, S. Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle //Biomaterials. – 2021. – Vol. 266. – P. 120381
    DOI:10.1016/j.biomaterials.2020.120381
    https://www.sciencedirect.com/science/article/pii/S014296122030627X
  5. Oroujeni, M., Rinne, S.S., Vorobyeva, A., Loftenius, A., Feldwisch, J., Jonasson, P., Chernov, V., Orlova, A., Frejd, F.Y., Tolmachev, V. Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake //International Journal of Molecular Sciences. – 2021. – Vol. 22. –  No. 2770.
    DOI:10.3390/ijms22052770 
    https://www.mdpi.com/1422-0067/22/5/2770
  6. Abouzayed, A., Rinne, S. S., Sabahnoo, H., Sörensen, J., Chernov, V., Tolmachev, V., Orlova, A. Preclinical Evaluation of 99mTc-Labeled GRPR Antagonists maSSS/SES-PEG2-RM26 for Imaging of Prostate Cancer //Pharmaceutics. – 2021. – Vol. 13. – No. 2. – P. 182.
    DOI: 10.3390/pharmaceutics13020182  
    https://www.mdpi.com/1999-4923/13/2/182
  7. Oroujeni, M., Xu, T., Gagnon, K., Rinne, S.S., Weis, J., Garousi, J., Andersson, K.G., Löfblom, J., Orlova, A. and Tolmachev, V. Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR:2377 Affibody Molecule  //Pharmaceutics. – 2021. – Vol. 13. –  No. 292.
    DOI: 10.3390/pharmaceutics13020292 
    https://www.mdpi.com/1999-4923/13/2/292
  8. Rinne, S.S.; Leitao, C.D.; Abouzayed, A.; Vorobyeva, A.; Tolmachev, V.; Ståhl, S.; Löfblom, J.; Orlova, A. HER3 PET Imaging: 68Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to 89Zr-Labeled Antibody and Antibody-Fragment-Based Tracers. Cancers. – 2021. – Vol. 13.– P. 4791.
    DOI:10.3390/cancers13194791
    https://www.mdpi.com/2072-6694/13/19/4791
  9. Xu, T., Vorobyeva, A., Schulga, A., Konovalova, E., Vorontsova, O., Ding, H., Gräslund, T., Tashireva, L. A., Orlova, A., Tolmachev, V., & Deyev, S. M. Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model //Cancers.– 2021. – Vol. 13. – No. 16. – P. 3939. 
    DOI:10.3390/cancers13163939
    https://www.mdpi.com/2072-6694/13/16/3939
  10. Deyev, S. M., Xu, T., Liu, Y., Schulga, A., Konovalova, E., Garousi, J., Rinne, S. S., Larkina, M., Ding, H., Gräslund, T., Orlova, A., Tolmachev, V., & Vorobyeva, A. Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1 //Cancers.– 2021. – Vol. 13. – No. 14. – P. 3589. 
    DOI:10.3390/cancers13143589
    https://www.mdpi.com/2072-6694/13/14/3589
  11. Liu, Y., Vorobyeva, A., Xu, T., Orlova, A., Loftenius, A., Bengtsson, T., Jonasson, P., Tolmachev, V., & Frejd, F. Y. Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody® Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain  //Pharmaceutics.– 2021. – Vol. 13. – No. 6. – P. 839. 
    DOI:10.3390/pharmaceutics1306083
    https://pubmed.ncbi.nlm.nih.gov/34200197
  12. Rinne, S. S., Orlova, A., & Tolmachev, V. PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology //International journal of molecular sciences. – 2021. – Vol. 22. – No. 7. – P. 3663.
    DOI: 10.3390/ijms22073663
    https://www.mdpi.com/1422-0067/22/7/3663
  13. Rinne, S.S., Abouzayed, A., Gagnon, K., Tolmachev, V., Orlova, A. 66 Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [66 Ga] Ga-NOTA-PEG 2-RM26 //Scientific reports. – 2021. – Vol. 11. – No. 1. – P. 1-12. 
    DOI: 10.1038/s41598-021-82995-7
    https://pubmed.ncbi.nlm.nih.gov/33574368
  14. Oroujeni, M., Xu, T., Gagnon, K., Rinne, S.S., Weis, J., Garousi, J., Andersson, K.G., Löfblom, J., Orlova, A. and Tolmachev, V. Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR:2377 Affibody Molecule  //Pharmaceutics. – 2021. – Vol. 13. –  No. 292.
    DOI: 10.3390/pharmaceutics13020292 
    https://www.mdpi.com/1999-4923/13/2/292
  15. Abouzayed, A., Rinne, S. S., Sabahnoo, H., Sörensen, J., Chernov, V., Tolmachev, V., Orlova, A. Preclinical Evaluation of 99mTc-Labeled GRPR Antagonists maSSS/SES-PEG2-RM26 for Imaging of Prostate Cancer //Pharmaceutics. – 2021. – Vol. 13. – No. 2. – P. 182.
    DOI: 10.3390/pharmaceutics13020182  
    https://www.mdpi.com/1999-4923/13/2/182
  16. Oroujeni, M., Rinne, S.S., Vorobyeva, A., Loftenius, A., Feldwisch, J., Jonasson, P., Chernov, V., Orlova, A., Frejd, F.Y., Tolmachev, V. Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake //International Journal of Molecular Sciences. – 2021. – Vol. 22. –  No. 2770.
    DOI:10.3390/ijms22052770 
    https://www.mdpi.com/1422-0067/22/5/277
  17. Garousi, J., von Witting, E., Borin, J., Vorobyeva, A., Altai, M., Vorontsova, O., Konijnenberg, M.W., Oroujeni, M., Orlova, A., Tolmachev, V.  Hober, S. Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle //Biomaterials. – 2021. – Vol. 266. – P. 120381
    DOI:10.1016/j.biomaterials.2020.120381
    https://www.sciencedirect.com/science/article/pii/S014296122030627X
  18. Xu, T., Ding, H., Vorobyeva, A., Oroujeni, M., Orlova, A., Tolmachev, V., Graslung, T. Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model //Cancers. – 2021. – Vol. 13. – No. 85. – P. 1-21.
    DOI: 10.3390/cansers13010085  
    https://www.mdpi.com/2072-6694/13/1/85
  19. Tano, H., Oroujeni, M., Vorobyeva, A., Westerlund, K., Liu, Y., Xu, T., Vasconcelos, D., Orlova, A., Karlström, A.E., Tolmachev, V. Comparative Evaluation of Novel 177Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting //Cancers. – 2021. – Vol. 13. – No. 3. – P. 500. 
    DOI: 10.3390/cancers13030500  
    https://www.mdpi.com/2072-6694/13/3/500
  20. Tolmachev, V., Orlova, A., & Sörensen, J. The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer //Seminars in Cancer Biology. – Academic Press, 2021.   
    DOI: 10.1016/j.semcancer.2020.10.005 
     https://www.sciencedirect.com/science/article/pii/S1044579X20302108
  21. Ding, H., Xu, T.,  Zhang, J., Tolmachev, V., Oroujeni, M., Orlova, A., Gräslund, T., Vorobyeva, A. Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution //Pharmaceutics. – 2021. – Vol. 13. –  No. 430.
    DOI: 10.3390/pharmaceutics13030430.
    https://www.mdpi.com/search?q=Affibody-Derived+Drug+&journal=pharmaceutics
  22. Zelepukin, I.V., Popov, A.A., Shipunova, V.O., Tikhonowski, G.V., Mirkasymov, A.B., Popova-Kuznetsova, E.A., Klimentov, S.M., Kabashin, A.V.,  Deyev, S.M. Laser-synthesized TiN nanoparticles for biomedical applications: evaluation of safety, biodistribution and pharmacokinetics  //Materials Science and Engineering: C. – 2021. – Vol. 120.  – P. 111717.
    DOI:10.1016/j.msec.2020.111717 
    https://www.sciencedirect.com/science/article/pii/S0928493120336365
  1. Dudnikova Y.A., Chernov V.I., Muravleva A.V., Kravchuk T.L., Zelchan R.V., Medvedeva A.A., Bragina O.D., Simolina Y.L., Popova N.O., Vysockaja V.V., Lukina N.M., Shatalova V.A., Shpileva O.V., Goldberg A.V., Goldberg V.Y. Metabolic single-photon emission computed tomography with the new radiopharmceutical 99Tc-1-thio-D-glucose in the diagnosis and monitoring of the primary breast lymphoma (case report) //Siberian journal of oncology. – 2020. – Vol. 19. – No.5. – P. 145-153.
    DOI: 10.21294/1814-4861-2020-19-5-145-153 
    https://www.siboncoj.ru/jour/article/view/1589
  2. Dudnikova Y.A., Chernov V.I., Muravleva A.V., Kravchuk T.L., Zelchan R.V., Medvedeva A.A., Bragina O.D., Simolina Y.L., Popova N.O., Vysockaja V.V., Lukina N.M., Shatalova V.A., Shpileva O.V., Goldberg A.V., Goldberg V.Y. Metabolic single-photon emission computed tomography with the new radiopharmceutical 99Tc-1-thio-D-glucose in the diagnosis and monitoring of the primary breast lymphoma (case report) //Siberian journal of oncology. – 2020. – Vol. 19. – No.5. – P. 145-153.Vorobyeva, A., 
    DOI: 10.21294/1814-4861-2020-19-5-145-153
    https://www.siboncoj.ru/jour/article/view/1589?locale=en_US
  3. Vorobyeva, A., Bezverkhniaia, E., Konovalova, E., Schulga, A., Garousi, J., Vorontsova, O., Abouzayed, A., Orlova, A., Deyev, S., Tolmachev, V. Radionuclide molecular imaging of EpCAM expression in triple-negative breast cancer using the scaffold protein DARPin Ec1 //Molecules. – 2020. – Vol. 25. – No. 20. – P. 4719.
    DOI: 10.3390/molecules25204719
    https://www.mdpi.com/1420-3049/25/20/4719
  4. Bezverkhniaia, E.A., Povet’eva, T.N., Kadyrova, T.V., Suslov, N.I., Nesterova, Y.V., Ol’ga, G., Kul’pin, P.V., Yusova, Y.G., Ermilova, E.V., Miroshnichenko, A.G., Brazovskii, K.S. Screening study for anticonvulsive activity of lipophilic fractions from empetrum nigrum L. //Research Results in Pharmacology. – 2020. – Vol. 6.  – P.67
    DOI: 10.3897/rrpharmacology.6.55015
    https://cyberleninka.ru/article/n/screening-study-for-anticonvulsive-activity-of-lipophilic-fractions-from-empetrum-nigrum-l/viewer
  5. Shramova, E. I., Kotlyar, A. B., Lebedenko, E. N., Deyev, S. M., Proshkina, G. M. Near-Infrared Activated Cyanine Dyes As Agents for Photothermal Therapy and Diagnosis of Tumors.//Acta Nature. – 2020. – Vol. 12. – No. 3(46). – P. 102-113.
    DOI: 10.32607/actanaturae.11028 
    http://actanaturae.ru/2075-8251/article/view/11028
  6. Lundmark, F., Abouzayed, A., Mitran, B., Rinne, S.S., Varasteh, Z., Larhed, M., Tolmachev, V., Rosenström, U., Orlova, A. Heterodimeric radiotracer targeting PSMA and GRPR for imaging of prostate cancer—optimization of the affinity towards PSMA by linker modification in murine model //Pharmaceutics. – 2020. – Vol. 12. – No. 7. – P. 614.
    DOI: 10.3390/pharmaceutics12070614
    https://www.mdpi.com/1999-4923/12/7/614
  7. Shramova, E., Proshkina, G., Shipunova, V., Ryabova, A., Kamyshinsky, R., Konevega, A., Schulga, A., Konovalova, E., Telegin, G., Deyev, S. Dual targeting of cancer cells with darpin-based toxins for overcoming tumor escape //Cancers. – 2020. – Vol. 12. – No. 10. – P. 3014.
    DOI:10.3390/cancers12103014 
    https://www.mdpi.com/2072-6694/12/10/3014
  8. Mitran B., Tolmachev V., Orlova A. Radiolabeled grpr antagonists for imaging of disseminated prostate cancer. Influence of labeling chemistry on targeting properties //Current medicinal chemistry. – 2020. – Vol. 27. – No. 41. – P. 7090-7111.
    DOI: 10.2174/0929867327666200312114902 
    https://www.ingentaconnect.com/content/ben/cmc/2020/00000027/00000041/art00013;jsessionid=1v764c8qjxtbk.x-ic-live-01
  9. Garousi, J., Vorobyeva, A. and Altai, M., 2020. Influence of Several Compounds and Drugs on the Renal Uptake of Radiolabeled Affibody Molecules //Molecules. – 2020. – Vol. 25. – No. 11. – P. 2673.
    DOI: 10.3390/molecules25112673  
    https://www.mdpi.com/1420-3049/25/11/2673
  10. Vorobyeva, A., Oroujeni, M., Lindbo, S., Hober, S., Xu, T., Liu, Y., Rinne, S.S. and Garousi, J., 2020. Investigation of a pharmacological approach for reduction of renal uptake of radiolabeled adapt scaffold protein //Molecules. – 2020. – Vol. 25. – No. 19. – P. 4448.
    DOI:10.3390/molecules25194448
    https://www.mdpi.com/1420-3049/25/19/4448
  11. Trofimova, E.S., Zykova, M.V., Sherstoboev, E.Y., Danilets, M.G., Ligacheva, A.A. and Belousov, M.V. Effects of Humic Acids, Isolated from High-Moor Pine-Peat Moss-Cotton Grass Peat on the Production of Cytokines by Mouse and Human Immunocompetent Cells and on Humoral Immune Response // Bulletin of experimental biology and medicine. – 2020. – Vol. 168. – No. 5. – P. 651-653.
    DOI:10.1007/s10517-020-047722 .
    https://search.proquest.com/openview/2692d43b9f3d023a5faf9ed38ab29aea/1?cbl=47742&pq-origsite=gscholar
  12. Guler, R., Svedmark, S. F., Abouzayed, A., Orlova, A., & Lofblom, J. Increasing thermal stability and improving biodistribution of VEGFR2-binding affibody molecules by a combination of in silico and directed evolution approaches //Scientific reports. – 2020. – Vol. 10. – No. 1. – P. 1-14.
    DOI: 10.1038/s41598-020-74560-5
    https://www.nature.com/articles/s41598-020-74560-5
  13. Baun, C., Mitran, B., Rinne, S. S., Dam, J. H., Olsen, B. B., Tolmachev, V., Orlova, A. Thisgaard, H. Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer //Molecules. 2020. – Vol. 25. – No. 24. – P. 5993.
    DOI: 10.3390/molecules25245993 
    https://www.mdpi.com/1420-3049/25/24/5993
  14. Myrhammar, A., Vorobyeva, A., Westerlund, K., Yoneoka, S., Orlova, A., Tsukahara, T.,  & Altai, M. Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargeting //Scientific Reports. – 2020. – Vol. 10. – No. 1. – P. 1-12.
    DOI: 10.1038/s41598-020-77523-y
    https://www.nature.com/articles/s41598-020-77523-y
  15. Abouzayed, A., Tano, H., Nagy, A., Rinne, S.S., Wadeea, F., Kumar, S., Westerlund, K., Tolmachev, V., Karlstrom, A.E., Orlova, A. Preclinical evaluation of the grpr-targeting antagonist rm26 conjugated to the albumin-binding domain for grpr-targeting therapy of cancer // Pharmaceutics. – 2020. – Vol. 12. – No. 10. – P. 977.
    DOI: 10.3390/pharmaceutics12100977
    https://www.mdpi.com/1999-4923/12/10/977
  16. Leitao, C.D., Rinne, S.S., Altai, M., Vorontsova, O., Dunas, F., Jonasson, P., Tolmachev, V., Lofblom, J., Stahl, S., Orlova, A. Evaluating the therapeutic efficacy of mono-and bivalent affibody-based fusion proteins targeting HER3 in a pancreatic cancer xenograft model //Pharmaceutics. – 2020. – Vol. 12. – No. 6. – P. 551.
    DOI: 10.3390/pharmaceutics12060551
    https://www.mdpi.com/1999-4923/12/6/551
  17. Ding, H., Altai, M., Yin, W., Lindbo, S., Liu, H., Garousi, J., Xu, T., Orlova, A., Tolmachev, V., Hober, S., Graslund, T. HER2-specific pseudomonas exotoxin a pe25 based fusions: Influence of targeting domain on target binding, toxicity, and in vivo biodistribution //Pharmaceutics. – 2020. – Vol. 12. – No. 4. – P. 391.
    DOI: 10.3390/pharmaceutics12040391
    https://www.mdpi.com/1999-4923/12/4/391/htm
  18. Tolmachev, V., Orlova, A. Affibody molecules as targeting vectors for PET imaging //Cancers. – 2020. – Vol. 12. – No. 3. – P. 651.
    DOI: 10.3390/cancers12030651
    https://www.mdpi.com/2072-6694/12/3/651
  19. Rinne, S.S., Leitao, C.D., Saleh-Nihad, Z., Mitran, B., Tolmachev, V., Stahl, S., Lofblom, J., Orlova, A. Benefit of later-time-point PET imaging of her3 expression using optimized radiocobalt-labeled affibody molecules //International journal of molecular sciences. – 2020. – Vol. 21. – No. 6. – P. 1972.
    DOI: 10.3390/ijms21061972
    https://www.mdpi.com/1422-0067/21/6/1972
  20. Deyev, S.M., Vorobyeva, A., Schulga, A., Abouzayed, A., Gunther, T., Garousi, J., Konovalova, E., Ding, H., Graslund, T., Orlova, A., Tolmachev, V. Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1 //International Journal of Biological Macromolecules. – 2020. – Vol. 145. – P. 216-225.
    DOI: 10.1016/j.ijbiomac.2019.12.147
    https://www.sciencedirect.com/science/article/pii/S0141813019393808
  21. Rinne, S.S., Xu, T., Leitao, C.D., Stahl, S., Lofblom, J., Orlova, A., Tolmachev, V., Vorobyeva, A. Influence of residualizing properties of the radiolabel on radionuclide molecular imaging of HER3 using affibody molecules //International Journal of Molecular Sciences. – 2020. – Vol. 21. – No. 4. – P. 1312.
    DOI: 10.3390/ijms21041312
  22. Altai, M., Vorobyeva, A., Tolmachev, V., Karlstrom, A.E., Westerlund, K. Preparation of Conjugates for Affibody-Based PNA-Mediated Pretargeting //Peptide Nucleic Acids. – Humana, New York, NY, 2020. – P. 283-304.
    DOI: 10.1007/978-1-0716-0243-0_18
  23. Bragina, O.D., Vorobyeva, A.G., Tolmachev, V.M., Orlova, A.M., Chernov, V.I., Deyev, S.M., Proshkina, G.N., Shulga, A.A., Larkina, M.S., Medvedeva, A.A., Zelchan, R.V. In vitro and in vivo evaluation of the radiochemical compound based on 99m technetium labelled DARPin9_29 for molecular visualization of malignancies overexpressing Her2/neu [In vitro и in vivo оценка радиохимического соединения на основе меченного 99m-Tc каркасного белка  DARPin9_29 для молекулярной визуализации злокачественных образований с гиперэкспрессией Her2/neu] //Medical Radiology and Radiation Safety. – 2020. – Vol. 65. – No. 1. – P. 37-41.
    DOI: 10.12737/1024-6177-2020-65-1-37-41
    https://medradiol.fmbafmbc.ru/journal_medradiol/abstracts/2020/1/37-41_Bragina_et_al.pdf
  24. Vorobyeva, A., Konovalova, E., Xu, T., Schulga, A., Altai, M., Garousi, J., Rinne, S.S., Orlova, A., Tolmachev, V., Deyev, S. Feasibility of imaging epcam expression in ovarian cancer using radiolabeled darpin ec1 //International Journal of Molecular Sciences. – 2020. – Vol. 21. – No. 9. – P. 3310.
    DOI: 10.3390/ijms21093310
    https://www.mdpi.com/1422-0067/21/9/3310/htm
  25. Larkina, M.S., Ozerskaya, A.V., Podrezova, E.V., Belousov, M.V., Tolmachev, V., Zhdankin, V.V., Yusubov, M.S. Efficient Synthesis of w-[18F]Fluoroaliphatic Carboxylic Esters and Acids for Positron Emission Tomography //European Journal of Organic Chemistry. – 2020. – Vol. 2020. – No. 40. – P. 6375-6381.
    DOI: 10.1002/ejoc.202000934
    https://chemistry-europe.onlinelibrary.wiley.com/doi/full/10.1002/ejoc.202000934
  26. Alhuseinalkhudhur, A., Lubberink, M., Lindman, H., Tolmachev, V., Frejd, F.Y., Feldwisch, J., Velikyan, I., Sörensen, J. Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer //EJNMMI research. – 2020. – Vol. 10. – No. 1. – P. 1-10.
    DOI: 10.1186/s13550-020-0603-9
    https://ejnmmires.springeropen.com/articles/10.1186/s13550-020-0603-9
  1. Lar’kina, M.S., Krivoshchekov, S.V., Podrezova, E.V., Bragina, O.D., Chernov, V.I., Nesterov, E.A., Bodenko, V.V., Belousov, M.V., Yusubov, M.S. Validation of an Analytical HPLC Method for a New Diagnostic Octreotide Derivative for Neuroendocrine Tumors //Pharmaceutical Chemistry Journal. – 2019. – Vol. 53. – No. 9. – P. 865-870.
    DOI: 10.1007/s11094-019-02091-z
    https://link.springer.com/article/10.1007/s11094-019-02091-z